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Abstract
Aims/hypothesis. We examined the association be-
tween plasma insulin and cardiovascular mortality in
non-diabetic European men and women based on data
from eleven prospective studies.
Methods. The study population comprised 6156 men
and 5351 women aged 30–89 years. Baseline mea-
surements included oral glucose tolerance test, fasting
and 2-h plasma insulin, and conventional risk factors.
Cox models were used to calculate hazard ratios
(HRs) and their 95% confidence intervals, and overall
HRs were assessed by meta-analyses.
Results. During the 8.8-year follow-up, 362 men and
70 women died from cardiovascular disease. The age-
and smoking-adjusted overall HR of cardiovascular
mortality for the highest vs the lower quartiles of fast-
ing insulin was 1.58 (95% CI: 1.26–1.97) in men and
2.64 (1.54–4.51) in women. Adjusting for other risk
factors in addition, the HR was 1.54 (1.16–2.03) in
men and 2.66 (1.45–4.90) in women. For 2-h insulin
these HRs were 1.28 (0.99–1.66), 1.87 (0.87–4.02),
and 0.85 (0.60–1.21), 1.36 (0.53–3.45). The overall
HRs for interquartile ranges for fasting and 2-h insu-
lin, with full adjustment, were 1.13 (1.05–1.22) and
1.11 (1.01–1.23) in men, and 1.25 (1.08–1.45) and
1.11 (0.91–1.36) in women.
Conclusions/interpretation. Hyperinsulinaemia, defined
by the highest quartile cut-off for fasting insulin, was
significantly associated with cardiovascular mortality
in both men and women independently of other risk
factors. Associations between high 2-h insulin and
cardiovascular mortality were weaker and non-signifi-
cant. Weak positive associations of fasting and 2-h 
insulin with cardiovascular mortality over interquar-
tile ranges were, however, more similar.
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Introduction
The role of hyperinsulinaemia as an independent risk
factor for cardiovascular disease (CVD) has previous-
ly been debated. An association between elevated
plasma insulin, fasting or oral glucose load, and the
risk of CHD or atherosclerotic CVD has been found in
many [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16] but not in all [17, 18, 19, 20, 21] prospective stud-
ies. Among the studies showing the positive associa-
tion between plasma insulin and CVD, the effect of
adjustment for other risk factors has varied. In several
studies the association remained statistically signifi-
cant, although attenuated [1, 2, 3, 5, 6, 7, 9, 10, 12, 13,
15, 16] , whereas in other studies it became non-sig-
nificant [4, 8, 11, 14]. The majority of the published
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studies were carried out in male populations, while
some studies presented results for men and women
combined. Therefore, data on the association between
hyperinsulinaemia and CVD risk in women is scarce
and conflicting. Six studies reported results for men
and women separately [2, 8, 10, 12, 17, 19], but only
two of them demonstrated the association between 
hyperinsulinaemia and CVD risk in women [8, 12].
Hyperinsulinaemia is the consequence of the un-
derlying resistance of the tissues, mainly the skeletal
muscle, to the action of insulin [22, 23]. Hyperin-
sulinaemia and insulin resistance are closely linked 
to several physiological and biochemical risk factors
including overall and central obesity, impaired glu-
cose regulation, dyslipidaemia characterised by high
triglycerides and low HDL cholesterol, and elevated
blood pressure [23]. A concept has been developed
whereby this clustering of risk factors associated with
Type 2 diabetes and CVD forms a distinct syndrome
which has become known as “the insulin resistance
syndrome”, “the metabolic syndrome” or “the multi-
ple metabolic syndrome” [24]. The upsurge in re-
search and clinical interest in this field has refocused
attention to the results of prospective studies on the
association between plasma insulin levels and CVD
risk, particularly as measurement of fasting insulin has
been recommended as a surrogate estimate of insulin
resistance in epidemiological studies [25]. In the pres-
ent study we report results of meta-analyses of the as-
sociation of fasting insulin and 2-h post-glucose insu-
lin with cardiovascular mortality in non-diabetic Euro-
pean men and women based on data from eleven
prospective studies. The main aims of our study were
to examine whether the association between plasma
insulin level and cardiovascular mortality is (i) similar
for fasting insulin and 2-h insulin, and (ii) similar in
men and women.
Subjects and methods
Study populations and baseline study methods. Centres in Eu-
rope that had performed population-based studies or large
studies in occupational groups using the standard 2-h 75-g 
oral glucose tolerance test were invited to participate in the
DECODE (Diabetes Epidemiology: Collaborative analysis Of
Diagnostic criteria in Europe) study. The study populations and
the methods used to recruit the participants have been de-
scribed previously [26, 27, 28, 29, 30]. Individual data on fast-
ing and 2-h glucose concentrations and a number of other vari-
ables were sent to the Diabetes and Genetic Epidemiology Unit
of the National Public Health Institute in Helsinki, Finland for
data analyses. The present study is based on data from eleven
prospective studies, which are listed in Table 1. Eight of these
studies had data for both men and women. All studies mea-
sured fasting plasma insulin at the baseline examination, and
ten studies also measured 2-h insulin after an oral glucose tol-
erance test with 75 g glucose. All studies had baseline data on
BMI, blood pressure, serum triglycerides or HDL cholesterol
or both of these lipids, total cholesterol and smoking status, as
well as follow-up data on CVD mortality. HDL cholesterol
was not measured in the Helsinki Policemen Study. All investi-
gations were carried out in accordance with the Declaration of
Helsinki.
Because the DECODE studies started at different times in-
dependently of each other there was no standardisation of bio-
chemical measurements between study centres. Thus, methods
used for the measurement of plasma insulin were not uniform.
The types of insulin assays used in the different studies are
given in Table 2. Seven studies used conventional radioim-
munoassays, which measure immunoreactive insulin and
cross-react with proinsulin and its split products and are thus
called “non-specific” for intact (true) insulin. Four studies used
a radiometric assay or an ELISA that was “specific” for intact
insulin. In our study we also used the score of homeostasis
model assessment of insulin resistance (HOMA-IR; fasting 
insulin [µU/ml] × fasting plasma glucose [mmol/l]/22.5) as a
surrogate measure for insulin resistance [31]. For statistical
analyses, quartile cut-off points for fasting and 2-h insulin and
HOMA-IR were calculated in each cohort for men and women
separately.
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Table 1. Demographic characteristics of subjects, median duration of follow-up and number of cardiovascular deaths in eleven
DECODE study cohorts
Study cohort Number of Median age in Men (%) Median  Number of cardio-
subjects years (range) duration of vascular deaths
follow-up 
(years) Men Women
FINMONICA, Finland 1626 54 (44–64) 45 8.9 25 5
Helsinki Policemen Study, Finland 968 49 (34–74) 100 12.0 59
East-West Study, Finland 300 75 (70–89) 100 8.1 73
Northern Sweden MONICA, Sweden 1504 49 (30–74) 48 6.9 11 4
POLMONICA, Poland 319 58 (44–73) 47 6.4 13 2
Hoorn Study, The Netherlands 2162 61 (49–77) 46 8.9 59 24
Zutphen Study, The Netherlands 398 75 (69–89) 100 4.7 42
Newcastle Study, UK 697 55 (30–76) 51 9.0 21 5
Goodinge Study, UK 958 53 (39–76) 44 8.7 25 11
Ely Study, UK 1006 54 (40–69) 43 11.8 14 5
Cremona Study, Italy 1569 56 (40–88) 44 6.3 20 14
Total 11507 56 (30–89) 54 8.8 362 70
Subjects who had diabetes at baseline were excluded from
the present analyses. For diagnosis, we used the 1999 WHO
criteria [32]: previous diagnosis of diabetes or a fasting plasma
glucose of ≥7.0 mmol/l and/or a 2-h plasma glucose of
≥11.1 mmol/l.
Follow-up. Vital status was recorded for each subject who at-
tended the baseline examination. Subjects who had emigrated
and for whom vital status could not be confirmed were exclud-
ed from analyses at the time of emigration. The follow-up was
almost complete (98–100%) [28]. The Eighth, Ninth and Tenth
Revisions of the International Classification of Diseases were
used for coding the causes of death. The codes used for CVD
were 401–448 (I10–I79).
Statistical analysis. Data analyses were performed using the
SPSS for Windows 11.0 software. Associations of fasting and
2-h plasma insulin and HOMA-IR with other continuous risk
factors were assessed by calculating Spearman’s rank correla-
tion coefficients, adjusted for age and cohort, in the pooled
study population. The associations of conventional risk factor
variables with cardiovascular mortality in men and women of
the pooled study population were assessed by the Cox propor-
tional hazards model. Age- and cohort-adjusted and multivari-
ate-adjusted Cox model hazard ratios (HRs) and 95% CIs with
regard to the risk of cardiovascular mortality were calculated
for each risk factor, separately for men and women. The rela-
tionship of fasting insulin, 2-h insulin and HOMA-IR with car-
diovascular mortality was assessed by Cox models. Insulin
variables and HOMA-IR score were entered into Cox models
as dichotomous variables comparing the highest sex- and 
cohort-specific quartile for each variable with the respective
combined quartiles 1–3. Cox model analyses were also per-
formed by calculating HRs and 95% CIs for sex- and cohort-
specific interquartile ranges for fasting and 2-h insulin. Cox
models were adjusted for different sets of covariates including,
as appropriate, age, smoking, BMI, systolic blood pressure,
fasting glucose, 2-h glucose, total and HDL cholesterol, and
triglycerides (log-transformed). In the pooled database analy-
ses, the study cohort was also entered as a covariate. The pos-
sibility of a curvilinear association between insulin variables
and cardiovascular mortality was tested by the log-likelihood
ratio test comparing Cox models without and with squared
term for the relevant insulin variable.
Meta-analyses were performed to assess the overall associ-
ation of fasting insulin, 2-h insulin and HOMA-IR with car-
diovascular mortality using a fixed-effects approach and the 
methods detailed by Fleiss [33]. The results are reported as
overall HRs and 95% CIs for cardiovascular mortality. In the
meta-analyses of data on women, only the seven studies where
at least four CVD deaths had occurred were included. A p
value of less than 0.05 was considered statistically significant.
Results
The study population comprised 6156 men and 5351
women aged 30–89 years. The number of subjects
from each of the eleven study cohorts, and their demo-
graphic characteristics, are given in Table 1.
There were marked differences in the sex-specific
medians and interquartile ranges of fasting insulin and
2-h insulin between cohorts (Table 2). The between-
cohort variation in the ratio of the highest to the low-
est quartile for fasting and 2-h insulin was, however,
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somewhat less marked (fasting insulin, 1.6–2.4 in men
and 1.6–2.3 in women; 2-h insulin, 2.3–3.4 in men
and 2.0–2.5 in women).
The age- and cohort-adjusted Spearman’s correla-
tion coefficients for the association of fasting and 2-h
plasma insulin and HOMA-IR with other continuous
risk factors in men and women of the pooled study
population are given in Table 3. Triglycerides, BMI
and glucose variables had strong positive correlations;
systolic blood pressure had somewhat weaker positive
correlations; and total cholesterol had only weak posi-
tive correlations with fasting and 2-h insulin and
HOMA-IR. Furthermore, HDL cholesterol had strong
inverse correlations with both fasting and 2-h insulin,
as well as with HOMA-IR. The correlations between
fasting insulin and HOMA-IR were almost perfect.
The correlations between 2-h insulin and 2-h glucose
were clearly stronger than the correlations between
fasting insulin and fasting glucose. There was no asso-
ciation between smoking status and fasting or 2-h in-
sulin; the age-, cohort- and BMI-adjusted prevalences
of current smoking, comparing subjects in the highest
quartile with those in the combined lower quartiles,
were 32.5% vs 33.5% (NS) in men and 22.5% vs
21.8% (NS) in women in these fasting insulin cate-
gories, and 30.7% vs 28.9% (NS) in men and 22.4%
vs 21.7% (NS) in women in the corresponding 2-h in-
sulin categories.
During the follow-up, which had a median duration
of 8.8 years, 362 men and 70 women died from CVD
(Table 1). Restricting the data analyses in women to
the studies where there were at least four CVD deaths
in women reduced the total number of CVD deaths in
women to 68. Because 2-h insulin data were available
only from a subsample of 472 subjects (230 men and
242 women) in the Hoorn Study, analyses dealing
with 2-h insulin were based on 295 cardiovascular
deaths in men and 33 cardiovascular deaths in women.
The associations of conventional risk factors with
cardiovascular mortality were assessed by calculating
univariate (age- and cohort-adjusted) and multivariate
Cox model HRs and 95% CIs (Table 4). In univariate
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Table 3. Age- and cohort-adjusted Spearman’s correlation coefficients of fasting insulin, HOMA-IR and 2-h insulin with other risk
factors in the pooled data
BMI Systolic Total  HDL Triglyc- Fasting 2-h  Fasting HOMA-
BP cholesterol cholesterol erides glucose glucose insulin IR
Men
Fasting insulin 0.32a 0.07a 0.03a −0.20a 0.21a 0.09a 0.10a 1.00 0.98a
HOMA-IR 0.34a 0.09a 0.04a −0.20a 0.22a 0.21a 0.14a 0.98a 1.00
2-h insulin 0.30a 0.11a 0.03a −0.22a 0.24a 0.17a 0.52a 0.56a 0.56a
Women
Fasting insulin 0.34a 0.08a 0.07a −0.23a 0.25a 0.16a 0.15a 1.00 0.98a
HOMA-IR 0.37a 0.11a 0.06a −0.23a 0.27a 0.32a 0.21a 0.98a 1.00
2-h insulin 0.29a 0.17a 0.04a −0.23a 0.25a 0.22a 0.46a 0.54a 0.57a
a p<0.05; HOMA-IR, homeostasis model assessment of insulin resistance
Table 4. Univariate and multivariate Cox model hazard ratios
(HRs) and their 95% CIs for conventional risk factors with 
regard to cardiovascular mortality in the pooled data, shown
according to sex (362 cardiovascular deaths among 6156 men
and 68 cardiovascular deaths among 5183 women)
Risk factor Men Womena
Univariate HR Multivariate HR Univariate HR Multivariate HR
(95% CI)b (95% CI)c (95% CI)b (95% CI)c
Current smoking (yes vs no) 1.48 (1.18–1.86) 1.67 (1.29–2.16) 2.79 (1.63–4.77) 3.00 (1.70–5.28)
BMI (kg/m2) 1.02 (0.99–1.05) 0.99 (0.95–1.03) 0.99 (0.94–1.05) 0.97 (0.92–1.03)
Systolic BP (10 mm Hg) 1.09 (1.04–1.15) 1.06 (1.01–1.12) 1.13 (1.02–1.26) 1.15 (1.03–1.29)
Fasting glucose (mmol/l) 1.09 (0.89–1.33) 1.01 (0.81–1.27) 1.16 (0.76–1.78) 0.93 (0.58–1.49)
2-h glucose (mmol/l) 1.08 (1.02–1.15) 1.07 (1.00–1.14) 1.08 (0.94–1.23) 1.07 (0.92–1.24)
Total cholesterol (mmol/l) 1.17 (1.07–1.28) 1.16 (1.04–1.31) 0.95 (0.78–1.16) 0.84 (0.66–1.06)
HDL cholesterol (mmol/l) 0.45 (0.31–0.67) 0.45 (0.29–0.72) 0.48 (0.24–0.97) 0.84 (0.36–1.96)
Triglycerides (1 log-unit) 2.79 (1.66–4.68) 1.16 (0.55–2.46) 4.56 (1.32–15.8) 5.59 (0.94–33.1)
a Only the studies in which the number of cardiovascular
deaths was at least four; b Adjusted for age and cohort; c Multi-
variate models include, in addition to age and cohort, all the
risk factors listed in the table; in analyses of men the Helsinki
Policemen study was excluded
analyses, positive associations with cardiovascular
mortality were found for smoking, systolic blood pres-
sure, 2-h glucose, total cholesterol and triglycerides in
men, and for smoking, systolic blood pressure and
triglycerides in women. Inverse associations were ob-
served in both men and women between HDL choles-
terol and cardiovascular mortality. With multivariate
adjustment the association between triglycerides and
cardiovascular mortality became non-significant in
both men and women, and the same applied to the as-
sociation between HDL cholesterol and cardiovascular
mortality in women.
Figure 1 shows Cox model HRs and 95% CIs for
cardiovascular mortality in men and women, adjusted
for age and cohort, in the pooled data by quartiles of
fasting insulin and 2-h insulin, with the lowest quartile
as a reference. In both sexes there was a significant 
increase in cardiovascular mortality with increasing
fasting insulin levels. Curvilinearity of these associa-
tions was tested but could not be confirmed (p values
>0.10 in log-likelihood ratio tests). No significant in-
crease in cardiovascular mortality with increasing 2-h
insulin levels was observed in either men or women.
Meta-analyses of the association of fasting insulin,
HOMA-IR and 2-h insulin with cardiovascular mor-
tality, comparing the highest quartile with combined
lower quartiles, are summarised in Table 5. The HRs
and 95% CIs are shown with three levels of adjust-
ment for other variables: Model 1, with adjustment for
age and smoking; Model 2, with additional adjustment
for BMI, systolic blood pressure, fasting and 2-h glu-
cose, and total cholesterol; and Model 3, with addi-
tional adjustment for HDL cholesterol and triglyc-
erides (in ten studies of men and seven studies of
women). The statistics for study-to-study variation in
effect size show that there was no significant hetero-
geneity in the outcomes among populations included
in the meta-analyses (all p values >0.10).
Plasma insulin and cardiovascular mortality 1249
Fig. 1. Age- and cohort-adjusted hazard ratios (95% CI) for
cardiovascular mortality according to sex in pooled DECODE
study cohorts by quartiles of fasting insulin (a) and 2-h insulin
(b), with the lowest quartile as a reference. The p values for
the trends were 0.001 in men and 0.008 in women for fasting
insulin, and 0.117 in men and 0.197 in women for 2-h insulin
With Model 1 adjustment, the overall HR for car-
diovascular mortality in the highest quartile vs com-
bined lower quartiles for fasting insulin was signifi-
cantly increased in both men and women and was not
further attenuated with Model 2 and Model 3 adjust-
ments. The results for HOMA-IR were almost similar,
as expected. The overall HR for cardiovascular mor-
tality in the highest quartile for 2-h insulin, however,
was not statistically significant and became markedly
reduced with Model 2 and Model 3 adjustments.
We assessed the possible influence of the type of in-
sulin assay (non-specific vs specific) by calculating
overall HRs for cardiovascular mortality in the highest
quartile vs combined lower quartiles for fasting insulin,
HOMA-IR, and 2-h insulin with Model 1 and Model 2
adjustments in the seven studies in men which used
non-specific assays, and in the four studies in men
which used specific assays (Table 5). The results were
not substantially influenced by the type of assay used.
To assess the association of fasting and 2-h insulin
with cardiovascular mortality in a comparable way
over a wider range of the distributions of the two vari-
ables (without log transformation) we calculated HRs
for individual studies and carried out meta-analyses
for sex- and cohort-specific interquartile ranges for
fasting and 2-h insulin with Model 2 adjustment
(Fig. 2). There was a wide variation in HRs between
studies. In men, the overall HRs for fasting insulin
and 2-h insulin were almost similar and were statisti-
cally significant. In women, the overall HR for fasting
insulin was statistically significant, whereas the over-
all HR for 2-h insulin was not.
Discussion
Our meta-analyses, based on data from eleven Euro-
pean prospective studies, showed a statistically signif-
icant positive association between fasting insulin and
cardiovascular mortality. It was similar in both non-
diabetic men and women, and was independent of
plasma glucose and other cardiovascular risk factors.
There was an increased CVD risk in subjects in the
highest quartile of fasting insulin as compared with
those in combined lower quartiles, and also a linear
increase in CVD risk over the fasting insulin distribu-
tion. The association between high 2-h insulin and
CVD risk was weaker and was not statistically signifi-
cant in the highest vs combined lower quartiles com-
parison. However, meta-analyses carried out using a
comparable measure for the increment in fasting and
2-h insulin, sex- and cohort-specific interquartile
1250 The DECODE Insulin Study Group:
Table 5. Meta-analyses of the association of fasting insulin, HOMA-IR and 2-h insulin (the highest quartile vs quartiles 1–3) with
cardiovascular mortality, expressed as overall hazard ratios (HRs) and their 95% CIs, shown according to sex
Overall HR (95% CI)
Fasting insulin HOMA-IR 2-h insulina
Men (eleven studies)
Model 1b 1.58 (1.26–1.97) 1.59 (1.27–1.98) 1.28 (0.99–1.66)
Model 2c 1.53 (1.19–1.97) 1.53 (1.20–1.97) 1.07 (0.79–1.45)
Model 3 (ten studies)d 1.54 (1.16–2.03) 1.58 (1.20–2.09) 0.85 (0.60–1.21)
Non-specific insulin assay (seven studies)
Model 1 1.46 (1.12–1.92) 1.43 (1.09–1.87) 1.19 (0.89–1.61)
Model 2 1.37 (1.01–1.87) 1.34 (0.98–1.81) 0.99 (0.70–1.40)
Specific insulin assay (four studies)
Model 1 1.82 (1.25–2.66) 1.94 (1.33–2.82) 1.59 (0.95–2.68)
Model 2 1.89 (1.24–2.88) 1.99 (1.31–3.04) 1.42 (0.75–2.69)
Women (seven studies)e
Model 1 2.64 (1.54–4.51) 2.40 (1.37–4.20) 1.87 (0.87–4.02)
Model 2 2.72 (1.51–4.89) 2.41 (1.32–4.39) 1.28 (0.52–3.15)
Model 3 2.66 (1.45–4.90) 2.35 (1.27–4.37) 1.36 (0.53–3.45)
a 2-h insulin data were not available from the Cremona Study;
in the Hoorn Study, 2-h insulin data were available only from a
subsample of 472 subjects (230 men, 242 women); b Adjust-
ment for age and smoking; c Model 1 plus additional adjust-
ment for BMI, systolic BP, fasting glucose (except in HOMA-
IR analyses), 2-h glucose and total cholesterol; d Model 2 plus
additional adjustment for HDL cholesterol and triglycerides;
Helsinki Policemen Study excluded; e Only the studies in which
the number of cardiovascular deaths was at least four. HOMA-
IR, homeostasis model assessment of insulin resistance
Fig. 2. Individual and overall hazard ratios (95% CI) for car-
diovascular mortality, calculated for sex- and cohort-specific
interquartile ranges, for fasting insulin in men (a) and women
(b) and for 2-h insulin in men (c) and women (d) of the 
DECODE study cohorts, adjusting for age, smoking, BMI,
systolic blood pressure, fasting glucose, 2-h glucose and total
cholesterol
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range (approximately 50 pmol/l for fasting insulin and
200 pmol/l for 2-h insulin), demonstrated a more simi-
lar weak positive association of fasting and 2-h insulin
with CVD risk. The overall HR for the interquartile
range increment in fasting insulin was 1.13 in men
and 1.25 in women, and for the respective increment
in 2-h insulin, 1.11 in both men and women. These
overall hazard ratios are of the same magnitude as the
summary relative risks reported from a previous meta-
analysis of the association between plasma insulin and
CVD risk based on studies identified from the litera-
ture [34]; in seven studies in Caucasoid populations
the summary relative risk of CVD per increment of 
50 pmol/l in fasting insulin was 1.18, and per incre-
ment of 250 pmol/l in non-fasting insulin it was 1.16,
increments corresponding to the respective interquar-
tile ranges in the Dutch population.
HOMA-IR score, developed from the mathematical
modelling of fasting plasma glucose and insulin con-
centrations [31], has recently been used as a surrogate
measure of insulin resistance in some epidemiological
studies examining the relationship between insulin 
resistance and CVD risk [12, 13, 16]. The results of
studies that validate HOMA-IR score when compared
with direct measures of insulin resistance are, how-
ever, conflicting. Some studies have reported a stronger
correlation of HOMA-IR than of fasting insulin with
directly measured insulin resistance [31, 35], whereas
in other studies HOMA-IR was not found to be better
than fasting insulin in this respect [36, 37]. In our study
cohorts, the Spearman’s rank correlation coefficients
between HOMA-IR and fasting insulin were ≥0.98.
Therefore, it is not surprising that in our meta-analyses,
the associations of HOMA-IR and fasting insulin with
cardiovascular mortality were almost identical.
In some recent studies, plasma concentrations of
proinsulin-like molecules have been shown to be asso-
ciated with an increased risk of CVD, even more
strongly than plasma concentration of intact insulin,
and also independently of intact insulin [14, 21, 38]. In
non-diabetic subjects, proinsulin and its split products
account for about 10% of all immunoreactive insulin-
like molecules [39]. Thus, the use of insulin assays that
cross-react with proinsulin-like molecules might influ-
ence the association between insulin and CVD risk. In
our meta-analyses the overall HRs for CVD death in
the highest vs combined lower quartiles of fasting in-
sulin, HOMA-IR and 2-h insulin were, however, rather
similar in studies using assays specific for intact insu-
lin and in those using non-specific methods.
It is well known that due to intra-individual short-
term and long-term variation in the levels of biologi-
cal risk factors, their measurement on a single occa-
sion, as was done in all of our studies, does not classi-
fy individuals accurately with regard to their ‘usual’
risk factor levels. Because of the fluctuations in the
measured values of risk factors, prospective studies
based on single risk factor measurements tend to 
underestimate the real association between the ‘usual’
level of a risk factor and the disease rate during the
follow-up, a phenomenon called the “regression dilu-
tion” effect [40, 41]. The intra-individual variation in
plasma insulin levels has been shown to be relatively
large [42]; in Dutch subjects with normal glucose 
tolerance the ratio of the standard deviation of the
test–retest difference to the median of plasma insulin
measured with a specific method was found to be
23/76 pmol/l for fasting insulin and 190/303 pmol/l
for 2-h insulin. These test–retest differences were pre-
dominantly determined by a real biological variation,
with analytical variation making only a minor contri-
bution. In our study the regression dilution effect may
have led to a substantial underestimation of the true
association between insulin and CVD risk, even more
so with 2-h insulin than with fasting insulin because
of the much larger biological variation in 2-h insulin.
This may explain why 2-h insulin showed a weaker
association with CVD risk than fasting insulin in our
meta-analyses. However, to some extent the weaker
association of 2-h insulin with CVD risk could also be
explained by a smaller power of analyses on 2-h insu-
lin; in one study 2-h insulin data were only available
from a subsample and in another study data were not
available at all, which led to a substantial reduction in
the number of endpoints.
In univariate and multivariate analyses carried out
in the pooled DECODE study populations the associa-
tions between conventional risk factors and CVD mor-
tality corresponded largely with expectations (Table 4).
In the meta-analyses of the associations of fasting and
2-h insulin with CVD mortality, multivariate adjust-
ments, including the conventional risk factors and also
the core components of the metabolic syndrome (BMI,
glucose, blood pressure, triglycerides and HDL choles-
terol), resulted only in a modest attenuation of the as-
sociation between fasting insulin and CVD mortality.
The association between 2-h insulin and CVD mortali-
ty was, however, substantially reduced by the adjust-
ment for other risk factors, particularly in the analysis
of the highest vs combined lower quartiles. It is possi-
ble that this greater effect of multivariate adjustment
on the association between 2-h insulin and CVD mor-
tality is mainly explained by the strong correlation be-
tween 2-h insulin and 2-h glucose levels. In the inter-
pretation of the outcomes of these meta-analyses it is
important to note that in addition to the core compo-
nents of the metabolic syndrome included in our multi-
variate adjustments, there are also other factors, such
as thrombogenic factors [43] and inflammation mark-
ers [44], that are strongly linked with hyperinsuli-
naemia and insulin resistance and, on the other hand,
with increased CVD risk. The possibility that an unac-
counted residual confounding by such factors had an
effect on our results cannot be excluded.
The finding in our study and in a number of previ-
ously published individual prospective studies [1, 2, 3,
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5, 6, 7, 9, 10, 12, 13, 15, 16] that the association be-
tween plasma insulin level and CVD risk is indepen-
dent of other risk factors is even compatible with the
view that insulin, through some mechanism, could
have a direct effect on the development of atheroscle-
rosis. In vitro studies of the cells of the arterial wall
have suggested that insulin could stimulate smooth
cell proliferation and binding of LDL cholesterol to
smooth muscle cells, fibroblasts and monocytes [45].
Animal experiments trying to produce atherosclerosis-
like arterial lesions by the administration of exoge-
nous insulin have, however, produced conflicting and
unconvincing results [45, 46, 47]. Furthermore, long-
term clinical trials in subjects with Type 2 diabetes,
testing the effects of different treatment modalities on
the occurrence of cardiovascular complications, have
not demonstrated any deleterious effect of insulin
treatment [48, 49]. An alternative explanation for the
independent association between insulin and CVD
risk could be that the underlying insulin resistance 
itself or some unidentified background factor leading
to insulin resistance and hyperinsulinaemia directly
enhances the development of atherosclerotic vascular
disease. There is evidence from cross-sectional studies
that insulin resistance measured by direct methods is
associated with ultrasonographically measured intima-
medial thickening of the arterial walls, even indepen-
dently of the risk factors belonging to the metabolic
syndrome [50, 51, 52]. Two prospective studies have
also reported findings suggesting that directly mea-
sured insulin resistance predicts CVD risk [53, 54].
Our study has several limitations. One limitation is
that the study populations included in our meta-analy-
ses were not identified in an orthodox way, by a
search of published studies in the literature. Instead
they were identified among studies participating in the
collaborative DECODE Study which was originally
started for other purposes. We have not, however,
been able to identify in this set of studies any ele-
ments of selection bias or heterogeneity that might
have distorted the association between insulin and
CVD risk. Another limitation is that baseline risk fac-
tor measurements were not carried out by methods
standardised between the study centres. With regard to
plasma insulin determinations, we tried to overcome
the diversity in the methods by the use of sex- and co-
hort-specific cut-offs for the fasting and 2-h insulin in
analyses based on insulin quartiles and interquartile
ranges. In any case, differences in the methods used in
risk factor measurements may have led to some dilu-
tion in the risk estimates. A further limitation of our
study is that we could not exclude individuals with
prevalent CVD, because baseline data collection was
not uniform in that respect. The associations between
risk factors and CVD events tend to become attenuated
to some extent after the clinical manifestation of CVD
for several reasons (survival bias, treatment effects
and the strong relationship of established CVD to the
risk of recurrent events). Thus, inclusion of people
with prevalent CVD may have led to some attenuation
of the association between insulin and CVD risk. An
important strength of our meta-analyses is that instead
of using aggregate data we were able to use data on
individuals, thus reducing the risk of spurious results
[55].
Our finding that the fasting plasma insulin concen-
tration, more consistently than the 2-h insulin concen-
tration, shows a positive correlation with CVD risk 
independently of other risk factors is of relevance in
relation to the proposal by the European Group for the
Study of Insulin Resistance (EGIR) [25] that fasting
hyperinsulinaemia could be used in the definition of
the metabolic syndrome as a proxy for insulin resis-
tance measured by the euglycaemic insulin clamp, as
originally proposed by the WHO Consultation [32].
According to the EGIR, insulin-resistant people could
be defined as those with fasting plasma insulin levels
above the highest plasma insulin quartile cut-off in the
non-diabetic background population, the cut-off used
in our highest vs combined lower quartiles meta-anal-
yses. Fasting plasma insulin concentration is, how-
ever, not a perfect surrogate marker for insulin resis-
tance. The correlation of fasting plasma insulin with
directly measured insulin resistance is about 0.60 and
thus fasting plasma insulin explains only about 40%
of the variance in insulin resistance [36, 56]. The cor-
relation between 2-h insulin and directly measured in-
sulin resistance is of a similar magnitude [36, 56].
These correlations are based on single plasma insulin
measurements and, as discussed earlier, such measure-
ments do not always give a correct estimate of the
‘usual’ plasma insulin level and, consequently, insulin
resistance for an individual. Furthermore, correlations
of plasma insulin levels and directly measured indices
of insulin resistance with other risk factor components
of the metabolic syndrome are not limited to the co-
existence of high levels of these risk factors with high
insulin levels and insulin resistance but extend over a
wider range of their distributions [57, 58]. The find-
ings of the present study indicate that the excess CVD
risk is not confined to the highest quartiles of plasma
insulin levels with CVD risk but rather is more linear
in character. Therefore, the inclusion of hyperinsuli-
naemia in the definition of the metabolic syndrome
may not make a major contribution in the prediction
of CVD risk. We have, in fact, shown in another study
based on the same eleven DECODE studies that inclu-
sion of hyperinsulinaemia (highest fasting insulin
quartile) in the definition of the metabolic syndrome,
in addition to the presence of two or more, or three or
more of its other core components, resulted only in a
modest improvement in the prediction of the CVD
risk, with a slightly improved specificity but a reduced
sensitivity and positive predictive value [59].
Poor inter-laboratory reproducibility of plasma in-
sulin measurements remains the greatest problem in
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the use of insulin in the prediction of CVD risk, as
was pointed out by the American Diabetes Associa-
tion’s Task Force on standardisation of the insulin as-
say [60]. With the introduction of assays specific for
intact insulin, the within-laboratory analytical preci-
sion has improved, but even with these assays, the use
of the same assay kits in different laboratories does
not always ensure comparable measurements. As em-
phasised by the Task Force, a central reference labora-
tory, ongoing sample exchange and rigorous quality
control would be needed to improve and maintain the
reliability of plasma insulin measurements.
In conclusion, our meta-analyses of prospective
data from eleven DECODE study populations have
demonstrated that hyperinsulinaemia, defined by the
highest quartile cut-off for fasting insulin, was signifi-
cantly and similarly associated with cardiovascular
mortality in non-diabetic men and women, indepen-
dently of other risk factors. In the corresponding high-
est vs combined lower quartiles meta-analyses, the as-
sociations between high 2-h insulin and cardiovascu-
lar mortality were weaker and non-significant. Weak
positive associations of fasting and 2-h insulin with
cardiovascular mortality over interquartile ranges
were, however, more similar.
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